Program
nemolizumab
Also written as “Nemolizumab”, “Nemolizumab 30 mg” and “nemolizumab (CIM331)”.
Its studies are mostly in Dermatitis, Atopic · Prurigo · Scleroderma, Systemic · Pruritus · Renal Insufficiency, Chronic, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Group | 205 open or running | phase 3since Jun 11, 2019 | Mar 29, 2017 | Dec 2026phase 2 · NCT07074977 |
| Hoffmann-La Roche | 10 open or running | phase 2since Oct 31, 2013 | Oct 31, 2013 | none ahead |
| Maruho | 10 open or running | phase 2since Jan 17, 2022 | Jan 17, 2022 | none ahead |
| The Skin Center Dermatology Group | 11 open or running | phase 4since Feb 1, 2026 | Feb 1, 2026 | Jun 2027phase 4 · NCT07396168 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Oct 31, 2013.
- Jun 11, 20193 phase 3 studiesGalderma Group · NCT03985943, NCT03989349, NCT03989206
- Dec 17, 2019Phase 3 study in Prurigo NodularisGalderma Group · NCT04204616 · 500 enrolled · United States, Austria, Belgium and more
- Apr 24, 2020Phase 2 study in Dermatitis, AtopicGalderma Group · NCT04365387 · 242 enrolled · United States
- Jul 30, 20202 phase 3 studies in PrurigoGalderma Group · NCT04501679, NCT04501666
- Sep 18, 2020Phase 2 study in Dermatitis, AtopicGalderma Group · NCT04562116 · 17 enrolled · United States, Bulgaria
- Jun 4, 2021Phase 2 study in Dermatitis, AtopicGalderma Group · NCT04921345 · 109 enrolled · United States, Denmark, Hungary and more
- Sep 13, 20213 phase 3 studiesGalderma Group · NCT05052983, NCT05056779, NCT05075408
- Jan 17, 2022Maruho's first study: phase 2 study in Scleroderma, SystemicNew to MaruhoMaruho · NCT05214794 · 6 enrolled · Japan
- Jun 1, 2022Phase 1 study in Dermatitis, AtopicGalderma Group · NCT05405985 · 192 enrolled · United States
- Jun 24, 20252 phase 2 studiesGalderma Group · NCT07074977, NCT07047690
- Feb 1, 2026The Skin Center Dermatology Group's first study: phase 4 study in Lichen PlanusNew to The Skin Center Dermatology GroupThe Skin Center Dermatology Group · NCT07396168 · 10 planned · United States
- May 28, 2026Phase 2 study in Moderate-to-Severe Atopic DermatitisGalderma Group · NCT07660835 · 35 planned · United States
- Aug 10, 2026Phase 3 study in Dermatitis, AtopicGalderma Group · NCT07762833 · 240 planned · China
- Oct 16, 2026Primary completion moved from 2027-09-28 to 2027-10-28Date moved laterphase 3 · +1 months · NCT07762833
Ahead
- Dec 2026Primary completion: phase 2 study in Chronic Pruritus of Unknown OriginGalderma Group · NCT07074977
- Jun 2027Primary completion: phase 4 study in Lichen PlanusThe Skin Center Dermatology Group · NCT07396168
- Oct 28, 2027Primary completion: phase 3 study in Dermatitis, AtopicGalderma Group · NCT07762833
- May 28, 2028Primary completion: phase 2 study in Scleroderma, SystemicGalderma Group · NCT07047690
TargetBeta
“Interleukin-31 receptor subunit alpha inhibitor”ChEMBL 37, by rule
Other programs on IL31RA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
All 23 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07762833Dermatitis, Atopic · China | 3 | Recruiting | Galderma Group | Oct 28, 2027 | 240 |
| NCT07660835Moderate-to-Severe Atopic Dermatitis · United States | 2 | Recruiting | Galderma Group | Jul 15, 2028 | 35 |
| NCT07396168Lichen Planus · United States | 4 | Recruiting | The Skin Center Dermatology Group | Jun 2027 | 10 |
| NCT07074977Chronic Pruritus of Unknown Origin · United States, Canada | 2 | Active, not recruiting | Galderma Group | Dec 2026 | 50 |
| NCT07047690Scleroderma, Systemic · United States, Switzerland | 2 | Recruiting | Galderma Group | May 28, 2028 | 162 |
| NCT05405985Dermatitis, Atopic · United States | 1 | Completed | Galderma Group | Nov 11, 2022 | 192 |
| NCT05214794Scleroderma, Systemic · Japan | 2 | Completed | Maruho | Jun 4, 2024 | 6 |
| NCT05075408Renal Insufficiency, Chronic · United States, Hungary, Poland and more | 3 | Completed | Galderma Group | Jan 4, 2024 | 258 |
| NCT05056779Moderate-to-severe Atopic Dermatitis | 3 | Withdrawn | Galderma Group | Jul 2023 | 0 |
| NCT05052983Prurigo Nodularis · United States, Austria, France and more | 3 | Completed | Galderma Group | Sep 11, 2023 | 34 |
| NCT04921345Dermatitis, Atopic · United States, Denmark, Hungary and more | 2 | Completed | Galderma Group | Apr 28, 2025 | 109 |
| NCT04562116Dermatitis, Atopic · United States, Bulgaria | 2 | Completed | Galderma Group | Jun 7, 2023 | 17 |
| NCT04501679Prurigo · United States, Belgium, Canada and more | 3 | Completed | Galderma Group | Mar 30, 2022 | 274 |
| NCT04501666Prurigo · United States, Austria, Canada and more | 3 | Completed | Galderma Group | Nov 11, 2022 | 286 |
| NCT04365387Dermatitis, Atopic · United States | 2 | Completed | Galderma Group | Jul 7, 2023 | 242 |
| NCT04204616Prurigo Nodularis · United States, Austria, Belgium and more | 3 | Active, not recruiting | Galderma Group | Oct 26, 2026 | 500 |
| NCT03989349Dermatitis, Atopic · United States, Belgium, Bulgaria and more | 3 | Completed | Galderma Group | Feb 23, 2022 | 787 |
| NCT03989206Moderate-to-Severe Atopic Dermatitis · United States, Australia, Austria and more | 3 | Completed | Galderma Group | Aug 31, 2026 | 1,935 |
| NCT03985943Dermatitis, Atopic · United States, Australia, Austria and more | 3 | Completed | Galderma Group | Dec 29, 2021 | 941 |
| NCT03921411Dermatitis, Atopic · United States | 2 | Completed | Galderma Group | Aug 19, 2020 | 20 |
| NCT03181503Prurigo Nodularis · Austria, France, Germany and more | 2 | Completed | Galderma Group | Sep 26, 2018 | 70 |
| NCT03100344Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | Galderma Group | Jul 19, 2018 | 226 |
| NCT01986933Dermatitis, Atopic · United States | 2 | Completed | Hoffmann-La Roche | Apr 2015 | 264 |
How it is read
Names in the registry
- “Nemolizumab”, 20 entries
- “Nemolizumab 30 mg”, 2 entries
- “nemolizumab”, 2 entries
- “nemolizumab (CIM331)”, 1 entry
- “CD14152 Dose A”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 13 studies
- Prurigo, 5 studies
- Scleroderma, Systemic, 2 studies
- Pruritus, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.